3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Pulmonary Nodules
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Barrett Esophagus
1
Adenocarcinoma
1
Interventions
Gemcitabine
14
Cisplatin
13
Capecitabine
11
Oxaliplatin
9
Fluorouracil
9
130-nm albumin-bound paclitaxel
9
Paclitaxel
8
pembrolizumab
7
Ramucirumab
6
Leucovorin
6
Carboplatin
6
Bevacizumab
6
Albumin-Bound Paclitaxel
6
Pemetrexed
4
Nivolumab
4
Irinotecan
4
Everolimus
4
Erlotinib Hydrochloride
4
Docetaxel
4
Cyclophosphamide
4
trastuzumab deruxtecan
3
Radiotherapy
3
Afatinib
3
zolbetuximab
2
pralsetinib
2
cabozantinib
2
Trastuzumab
2
Ipilimumab
2
vosaroxin
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma
×
Diagnostic Imaging
×
Clear all
NCT00795184
2016-05-03
DONTBIOPCE
Mauna Kea Technologies
Phase NA
Completed
122 enrolled
5 charts